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An increased rate of de novo copy number variants (CNVs) has been found in schizophrenia (SZ), autism and
developmental delay. An increased rate has also been reported in bipolar affective disorder (BD). Here, in a
larger BD sample, we aimed to replicate these findings and compare de novo CNVs between SZ and BD. We
used Illumina microarrays to genotype 368 BD probands, 76 SZ probands and all their parents. Copy number var-
iants were called by PennCNV and filtered for frequency (<1%) and size (>10 kb). Putative de novo CNVs were
validated with the z-score algorithm, manual inspection of log R ratios (LRR) and qPCR probes. We found 15
de novo CNVs in BD (4.1% rate) and 6 in SZ (7.9% rate). Combining results with previous studies and using a
cut-off of >100 kb, the rate of de novo CNVs in BD was intermediate between controls and SZ: 1.5% in controls,
2.2% in BD and 4.3% in SZ. Only the differences between SZ and BD and SZ and controls were significant. The
median size of de novo CNVs in BD (448 kb) was also intermediate between SZ (613 kb) and controls (338 kb),
but only the comparison between SZ and controls was significant. Only one de novo CNV in BD was in a con-
firmedSZ locus (16p11.2).Sporadic or earlyonsetcases werenotmore likely to havedenovoCNVs.Weconclude
that de novo CNVs play a smaller role in BD compared with SZ. Patients with a positive family history can also
harbour de novo mutations.
INTRODUCTION
Bipolar affective disorder (BD)has a life-time riskof1%in the
general population and a 10-fold increased risk in first-degree
relatives (1). The heritability estimates range between 59 and
87% (2–4). It is a complex genetic disorder, with a high
degree of genetic and phenotypic heterogeneity (5). Genome-
wide association studies based on common genetic variants
have identified anumber of loci at compelling levels of statistical
support (6–10). It has been estimated that about a third of the
genetic variance in risk is contributed by common alleles that
are tagged by SNPs on genotyping arrays (11).
Rare, moderate to highly penetrant copy number variants
(CNVs) have been clearly established as risk factors for
several neuropsychiatric disorders: schizophrenia (SZ), autism
spectrum disorder and intellectual disability/developmental
delay (ID/DD) (12–16). Therefore, CNVs may also account
for some of the unexplained heritability of BD. Studies on BD
have yielded conflicting results, with modest enrichments for
CNVs in some studies but not in others (17–22). An enrichment
of de novo CNVs in individuals with BD was first reported by
Malhotra et al. (21) This team identified 10 CNVs in 185 pro-
bands, a rate of 5.4% (or 4.3% rate per person, as 2 probands
had 2 CNVs each), compared with 4 CNVs in 426 controls
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(a rate of 0.9%) suggesting that this class of variants is involved
in the disorder, particularly in early-onset cases. More recently,
Noor et al. (23) found 8 de novoCNVs among 215BDprobands,
a rate of 3.7%.No new control groupwas tested in that study, but
the rate was considered increased compared with control rates
from previous studies of 1–2%.
We aimed to investigate the role of de novo CNVs in the aeti-
ology of BD in the largest sample of BD parent-proband trios
tested to date and compare them with de novo CNVs found in
SZ patients.
RESULTS
We genotyped 368 BD and 76 SZ probands and all their parents
[after quality control (QC) filtering]. We successfully validated
21 de novo CNVs: 13 deletions and 8 duplications (Table 1).
Of those, 15 were found in BD probands, a rate of 4.1% (2.4%
for CNVs .100 kb) and 6 in SZ probands, a rate of 7.9%
(6.4% for CNVs .100 kb). These differences were not signifi-
cant, but the current sample sizes were clearly too small. One
BD proband had two de novo CNVs, so the de novo can also
be expressed as affecting 14 of 368 (3.8%) probands. We then
analysed the current data together with those from four
previous de novo CNV studies in BD and/or SZ (Table 2). In
order to be conservative in the analysis, we restricted the data
to large CNVs (.100 kb), as smaller ones might not have
been called with some of the arrays used in the previous
studies. Using the .100-kb cut-off, the de novo rates were 1.5,
2.2 and 4.3% in controls, BD and SZ, respectively (Fig. 1
and Table 2). The differences between SZ and BD and between
SZ and controls were significant (P ¼ 0.015 and 4.3 × 1027,
respectively); however, the increase in the de novo rate in BD
over controlswas not significant (P ¼ 0.21, Table 2). For comple-
tion, we also present the results for CNVs of.10 kb (Table 2 and
Fig. 1) but consider these comparisons less reliable, owing to the
stronger potential bias caused by different array coverage. Using
the .10-kb cut-off, the overall rate of de novo CNVs in BD was
higher than the rate in controls (4.3 versus 2.0%, P ¼ 0.00065)
and lower than in SZ (4.3 versus 5.9%, P ¼ 0.14).
The median size of de novo CNVs was 189 kb in BD and
640 kb in SZ, but this difference was not significant (Mann–
Whitney U-test, P ¼ 0.12). When results were combined with
those from previous studies, and a threshold of .100 kb was
applied as mentioned above, CNVs in BD were intermediate in
size between controls and SZ with medians of 338, 448 and
613 kb in controls, BD and SZ, respectively. Only the SZ/
controls difference was significant (P ¼ 0.001). The trend for
SZ patients to have larger de novo CNVs is also clear from the
Kaplan–Meier survival graph in Supplementary Material,
Figure S1.
Unexpectedly, the rate ofdenovoCNVswashigher in familial
cases compared with sporadic ones, both in BD (10.0 versus
3.1%, P ¼ 0.039) and in SZ (10.8 versus 5.1%, P ¼ 0.42).
When we combined our results with the previous ones, the
rates of de novo CNVs were not significantly different between
familial and sporadic cases: for SZ: 5.2 versus 5.9%, P ¼ 0.87;
and forBD:6.4versus 3.3%,P ¼ 0.16 (SupplementaryMaterial,
Table S2). There was a non-significant trend for parents of
de novo BD carriers to have been older at the time of birth of
their offspring: average paternal age ¼ 31.3 years (SD ¼ 7.4)
versus 28.8 (SD ¼ 5.5), P ¼ 0.1, and average maternal age ¼
27.8 (SD ¼ 6.6) versus 25.6 (SD ¼ 5.2), P ¼ 0.13. A small
trend in the same direction has also been reported in a larger
CNV study on probands with intellectual disability (26).
Table 1. De novo CNVs detected in this study
Diagnosis Cytoband Chr Start End Sample_ID CNV
type
CNV
size (bp)
Family_type FH Genes
BD 2q31.1 2 175365518 175813657 6038-3 del 448 139 UK BD Sibling Sibling WIPF1, CHRNA1,
CHN1
BD 5q15 5 92414916 95724985 1702-1 dupl 3 310 069 BG BD Trio No 18 genes
BD 6p22.3 6 23671880 23724469 6008-1 dupl 52 589 UK BD Trio No 0
BD 9p21.3 9 23765046 23953634 6194-1 del 188 588 UK BD Trio No ELAVL2
BD 10p14 10 6968905 6985007 1421-1 dupl 16 102 BG BD Trio Father 0
BD 10q21.1 10 56517409 56677171 602-1 del 159 762 UK BD Trio No PCDH15
BD 11q14.1 11 84139937 84345829 6320-1 del 205 892 UK BD Trio No DLG2
BD 16p13.3 16 6891681 6922307 6198-1 del 30 626 UK BD Trio No RBFOX1, intronic
BD 16p11.2 distal 16 28825605 29043450 3128-1 dupl 217 845 BG BD Trio No 12genes
BD 16p11.2 16 29595483 30198151 6023-9 dupl 602 668 UK BD Trio Father 31 genes
BD 17q23.1 17 57696973 57779678 1002-1 del 82 705 BG BD Trio No CLTC, PTRH2
BD 18q12.1 18 28277082 28375949 6194-1 dupl 98 867 UK BD Trio No 0
BD 19q12-q13.12 19 30861683 36685690 2283-1 dupl 5 824 007 BG BD Trio No 99 genes
BD 20p12.1 20 14771194 14853050 4052-1 del 81 856 BG BD Sibling sibling MACROD2, exonic
BD 22q11.21 22 21069073 21608479 5003-1 del 539 406 BG BD Trio Mother 14 genes
SZ 1q41 1 222152402 223209450 UK526-8 del 1 057 048 UK SZ Sibling Sibling 6 genes
SZ 2p16.3 2 50865334 51492973 4097-6 del 627 639 BG mixed Sibling NRXN1, exonic
SZ 15q24.3 15 77282884 77340328 UK516-4 dupl 57 444 UK SZ Sibling Sibling PSTPIP1, TSPAN3
SZ 22q11.21 22 18886915 21463730 UK1238-4 del 2 576 815 UK SZ Trio No VCFS region
SZ 22q11.22 22 22698552 23070912 UK602-4 del 372 360 UK SZ Sibling No 5 genes
SZ 22q11.22 distal 22 22998337 23651318 UK662-4 del 652 981 UK SZ Sibling Sibling 5 genes
All 21 de novo CNVs discovered and validated are sorted by diagnosis and genomic location. Cytoband, chromosome, start and end are listed according to UCSC
build 37, hg19. BG, Bulgaria, UK, United Kingdom.
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To provide a further comparison of CNVs between BD and
SZ, we assessed how many CNVs (transmitted or de novo)
were found in 15 CNV regions previously implicated in SZ
(12) in the BD and SZ probands in the current study (i.e. in
samples not used in the discovery of these associations). The
results are presented in Table 3. The overall rate of these
CNVs in BD is significantly lower (1.35%) than that in the SZ
sample (9%) (Fisher Exact test, P ¼ 0.0007), and on six occa-
sions, they were not transmitted to BD probands from carrier
parents. In contrast, there were no non-transmitted CNVs from
this list in the SZ sample. No person had twoCNVs from this list.
Oneprevious studyonBDfound an increased rate of singleton
deletions in subjects with an onset of illness before the age of 18
years (17). Another one (21) found an increased rate of de novo
CNVs in early-onsetBDcases. In the present study, themean age
at onset among BD probands with and without de novos was
practically identical (22.6 versus 22.8 years), with a similar dis-
tribution of ages (Fig. 2).
Gene pathway analyses in the combined datasets did not
reveal an enrichment of BD de novo CNV hits relative to
controlde novoCNVs after controlling formultiple testing (Sup-
plementary Material).
DISCUSSION
We have conducted the largest analysis of de novo CNVs in BD
to date (Table 2). We analysed BD and SZ families together, in
order to compare the de novo rates with the same methods and
arrays.
Frequency of de novo CNVs in BD
De novo CNVs were found in 4.1% of BD probands. This rate is
increased compared with controls from previous studies, but
lower than the 7.9% in SZ in the current sample. To obtain a
more meaningful comparison, we included in our analyses
data from previous large studies on de novo CNVs in SZ, BD
and controls. In order tominimise possible bias caused by differ-
ent array resolutions used in the different studies, we analysed
these differences for CNVs .100 kb (as these are more likely
to be detected by all arrays). Table 2 and Figure 1 show the
rates in these phenotypes in the combined data. The rate in BD
probands was intermediate between those in controls and SZ
(1.5 versus 2.2 versus 4.3%), although the rates in BD were not
significantly different from controls. Despite theweak statistical
support, both comparisons (with cut-offs of 10 and 100 kb) show
Table 2. Comparison of rates and sizes of CNVs with previous de novo CNV studies
N trios N CNVs (%) .10 kb Median size in kb .10 kb N CNVs (%) .100 kb Median size in kb .100 kb
Current study
BD 368 15 (4.1%) 189 9 (2.4%) 448
SZ 76 6 (7.9%) 640 5 (6.4%) 653
Malhotra et al. (21)
BD 185 10 (5.4%) 137 5 (2.7%) 611
SZ 177 9 (5.1%) 348 6 (3.4%) 824
CON 426 4 (0.9%) 41 1 (0.2%) 1425
Kirov et al. (24)
SZ 662 34 (5.1%) 321 25 (3.8%) 574
CON 2623 59 (2.2%) 259 46 (1.8%) 320
Xu et al. (25)
SZ 200 17 (8.5%) 260 12 (7.9%) 489
CON 159 2 (1.3%) 2804 2 (1.3%) 2804
Noor et al. (23)
BD 215 8 (3.7%) 76 3 (1.4%) 418
Totals/P-value
BD 768 33 (4.3%) 133 17 (2.2%) 448
SZ 1115 66 (5.9%) 356 48 (4.3%) 613
CON 3208 65 (2.0%) 259 49 (1.5%) 338
P-value, BD versus CON 0.00065 0.14 0.21 0.74
P-value, SZ versus CON 1.43 1029 0.54 4.33 1027 0.001
P-value, BD versus SZ 0.14 0.079 0.015 0.44
All rates refer to the number of CNVs in the sample (rather than the number of carriers of CNVs). CNVs on the X-chromosome are excluded.
Significant results are shown in bold.
Figure 1. Comparison of the de novo rates for CNVs .10 and .100 kb in
controls (CON), BD and SZ, based on the studies listed in Table 2.
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similar trends, with the rates of de novoCNVs inBDbeing inter-
mediate between controls and SZ (Fig. 1).
Potential role of specific CNVs in BD
The trendwe observed for an increased rate of de novoCNVs in
BD compared with controls is consistent with a small propor-
tion of these loci playing a role in the pathogenesis of the dis-
order. The more likely candidate loci are the following: the
deletion at DLG2, a gene implicated in SZ (24) and BD (23);
the duplication at 16p11.2, as it is also implicated in SZ and
BD (13,21) [our proband with de novo duplication was
among the cases used in the original case–control study that
found an association with BD (13)]; the duplication of the
‘distal 16p11.2’ locus, as it is an ID locus, while the reciprocal
deletion is both an SZ and ID locus (15,27); the deletion
at PCDH15, as mutations in this gene can cause deafness
and Usher syndrome Type IF (http://omim.org/entry/602083),
a disorder with a possibly increased rate of psychosis and
behavioural problems (28,29).
CNVs in BDmight be less pathogenic than those found in SZ
Overall de novo CNVs tended to be smaller in BD (median of
448 kb) than in SZ (median of 613 kb) in the combined datasets
(Table 2). The lack of significance might be due to the small
sample sizes, as the distribution of CNV sizes suggests a trend
for CNVs in SZ to be larger (Supplementary Material, Fig.
S1). Previous case–control studies in BD also report that the
rate of very large (.1 Mb) and rare (,1%) CNVs in BD is
similar or even lower than that in controls (18,22).Only twodele-
tions and six duplications in BD probands in the current study
were .1 Mb (rates of 0.54 and 1.62%, respectively, including
transmitted CNVs). These rates are lower than those in previous
controls analysed by us with the same methods: among 11 255
controls in our recent study, we reported rates of 0.65 and
1.95%, respectively (30). A smaller proportion of CNVs in BD
probands were also found at 15 loci that have been shown to
be pathogenic for SZ and other neurodevelopmental disorders,
either as de novo, or inherited (Table 3). The cumulative rate
of 1.35% of these CNVs in BD patients is close to the 0.96%
rate we reported among 11 255 controls and lower than the
2.49% among 6882 SZ patients in our recent study (30). The
strongest difference between the two disorders is for 15q11.2
deletions, which were not transmitted from three unaffected
Table 3. Transmission status of CNVs at loci implicated in SZ [according to our review of the literature (12)]
Locus Position in Mb BD (N ¼ 371) SZ (N ¼ 78)
1q21.1 del chr1: 14 657–14 739 1 T from BD F
1q21.1 dup chr1: 14 657–14 739 1 T from healthy M
NRXN1 del chr2: 5015–5126 1 de novo
3q29 del chr3: 19 573–19 734
WBS dup chr7: 7274–7414
VIPR2 dup chr7: 15 882–15 894
15q11.2 del chr15: 2280–2309 3 NT from healthy parents 5 T (one M is SZ)
Angelman/Prader–Willi dup chr15: 2482–2843
15q13.3 del chr15: 3113–3248
16p13.11 dup chr16: 1551–1630 1 T
2 NT from healthy parents
16p11.2 distal del chr16: 2882–2905
16p11.2 dup chr16: 2964–3020 1 de novo
1 NT from healthy M
17p12 del chr17: 1416–1543 1 T from healthy F
17q12 del chr17: 3481–3620
22q11.2 del chr22: 1902–2026 1 de novo
Total in probands 5 (1.35%); 6 NT 7 (9%); 0 NT
The ‘Total in probands’ include transmissions + de novos.
T/NT, transmitted/not transmitted from a parent; M, mother; F, father.
Figure 2.Age at onset amongBDprobandswith de novoCNVs (black columns)
and without de novos (dashed columns).
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parents to their BDoffspring,whereas such deletionswere trans-
mitted from three parents (one affected with SZ) to five SZ off-
spring (including two affected SZ sib-pairs). In our previous
study on BD, we also found a particularly low rate of 15q11.2
deletions among 1697 cases (0.18%) (18), which is even lower
than the 0.28% in population controls (12). All these observa-
tions suggest that very large and rare CNVs, and those shown
to increase risk for SZ, ID and DD, play at best a very modest
role in BD.
Cases with a positive family history also have an increased
rate of de novo CNVs
It has generally been assumed that sporadic cases aremore likely
to carry de novo CNVs than familial cases. To test whether
de novoCNVs aremore common in sporadic cases, we stratified
the sample by history of BD/SZ/psychotic disorder in first-
degree relatives and found that the de novo CNV rate is not sig-
nificantly different between familial and sporadic cases; in fact,
it was higher in familial cases in the current study (Supplemen-
tary Material, Table S2). The first study of de novo CNVs in SZ
reported that they occur more frequently in sporadic cases (25),
but a subsequent study (21) found that the rates of de novoCNVs
inBDandSZcohortswere similar in sporadic and familial cases.
In our previous study on SZ (24), we considered the family
history as positive only if it was present in parents (reasoning
that siblings can have independent de novo CNVs) and found a
slightly higher rate in sporadic cases. Combining all these
studies and re-coding our previous data (24) to include cases
with affected siblings as well, we find that the rate of de novo
CNVs is similar in familial and sporadic cases: 5.2 versus
5.9% for SZ and 6.4 versus 3.3% for BD, respectively (the
increased rate in familial BD cases is not significant, P ¼ 0.16).
Two examples of de novo CNVs in family history-positive
cases are particularly striking. The 16p11.2 duplication has a
high penetrance of 34% for any neurodevelopmental disorder
(31) but was found in the daughter of a father who also suffers
with a severe form of BD (being de novo, that mutation is not
found in the father). The exonic NRXN1 deletion [penetrance
of 32% for any disorder (31)] was found in a SZ proband from
a multiply affected family: the proband’s sister had schizo-
affective disorder, she was married to a BD patient and her
daughter had BD. No other family member had a pathogenic
CNV.
In conclusion, this study confirms previous suggestions that
very large and rare CNVs, especially those implicated in neuro-
developmental disorders (such as most of the CNVs listed in
Table 3), play a lesser role in BD compared with SZ. However,
we did observe a non-significant trend for the rate of de novo
CNVs to be higher in BD than in controls, suggesting that
larger and more powerful studies might reveal a significant
excess. In addition, several of the loci impacted by de novo
CNVs have been previously implicated in neuropsychiatric dis-
orders, which enhance their credibility as candidates for BD.
These include 16p11.2, DLG2 and PCDH15. Finally, we also
observed an excess of de novo mutations in familial cases of
major psychiatric disorders. With hindsight this should not be
surprising, as disorders of complex genetic inheritance are not
due to single gene defects, but to an accumulation of a number
of susceptibility factors.
MATERIALS AND METHODS
Participants
The total sample (afterQC)filtering consists of 449probands: 368
withBD(256 fromBulgaria and112 from theUK)and76withSZ
(15 from Bulgaria and 61 from the UK). Three hundred and
eighty-one probands were from parent-offspring trios (342 with
BDand39withSZ),42were fromfamilieswith2affectedsiblings
(16withBDand 26withSZ) and 21 (10BDand11SZ)were from
families with more complex structures, including families with
a mixture of diagnoses (SupplementaryMaterial, Table S1). Pro-
bands affected with schizoaffective disorder were excluded from
this study. Probands with a history of psychosis in a sibling or
parent (50 with BD and 37 with SZ) were included, as none of
the risk CNVs identified to date is sufficiently penetrant to fully
explain the disorder in carriers (31), and therefore, we wanted to
test whether familial cases can also have de novoCNVs. The pro-
portion of affected sibling pairs with SZ from the UK is very high
because part of this cohort was recruited as affected sib-pairs for
linkage analysis, whereas all BD trios were recruited specifically
for studying parent-offspring trios.
The recruitment of families in Bulgaria has been described
before (24). Each proband had a history of hospitalisation and
was interviewed with an abbreviated version of the Schedules
for Clinical Assessment in Neuropsychiatry (SCAN) (32). Con-
sensusbest-estimate diagnosesweremadeaccording toDSM-IV
criteria by two researchers. This recruitment also included SZ
trios, which have been genotyped with Affymetrix arrays and
reported previously (24), apart fromsome familieswith different
diagnoses that are reported here. In theUK, theBDpatientswere
recruited and interviewed in person byGK, using the same rating
instruments. Consensus best-estimate diagnoses were made by
two researchers (G.K. and N.C.), based on the interview and
hospital notes. The SZ families from the UK were recruited
as part of sib-pair and case–control collections. The main
purpose for the inclusion of SZ probands in the current study is
to compare in an unbiased way (using identical methods), the
de novo CNV rate between BD and SZ, and also to enlarge the
sample of family history-positive cases, where fewer data are
available from previous studies. Ethics committee approval for
the studywas obtained from the relevant research ethics commit-
tees and all individuals provided written informed consent for
participation. A small proportion of the probands from the UK
have been included as cases in previous case–control studies:
55 BD probands are in the Grozeva et al. study (18) and 29 SZ
probands in the Kirov et al. study (33); however, they were not
evaluated for de novo CNVs. Comparisons with de novo CNVs
from healthy control populations were made with probands
from three previous studies (21,24,25).
Genotyping of blood-derived DNA from all samples was
performed at the Stanley Centre for Psychiatric Research at
the Broad Institute of MIT, USA on two arrays: HumanOmni
Express-12v1 (referred further for short as ‘OmniExpress
array’), containing 730 525 probes, and any poorly performing
sampleswere re-genotyped onHumanOmniExpressExome-8v1
(‘Combo array’), containing 951 117 probes. The Combo array
contains SNPs from both the Omni Express array and the Illu-
mina HumanExome-12v1_A (‘Exome array’); however, for
the analysis of Combo array data, we only used the probes
present on the OmniExpress array (N ¼ 699 865).
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CNV calling and QC
Raw intensity data were processed using Illumina Genome
Studio software (v2011.1). SNPs were clustered using the
current samples, and LRR and B-allele frequencies were gener-
ated for CNV detection. PennCNV (34) was used to call CNVs
following the standard protocol and adjusting for GC content.
Sample-levelQCwasperformedusing theQCmetrics generated
by PennCNV. These include: LRR standard deviation, B-allele
frequency drift, wave factor and total number of CNVs called
per person. Samples were excluded if for any one of these
metrics they constituted an outlier in their source dataset
(details not presented). All poorly performing samples were
re-genotyped on Combo arrays. If one family member making
up a trio was excluded, then we excluded the whole trio, thus
excluding 33 families.
All individualCNVsalsowent throughQCfiltering. First, raw
CNVs in the same sample were joined together if the distance
separating them was ,50% of their combined length. CNVs
were then excluded if they were either ,10 kb, covered by
,10 probes, overlapped with low copy repeats by .50% of
their length (using PLINK) (35) or had a probe density of
.20 kb per probe. The remaining CNVs from each dataset
were then analysed together and CNV loci with a frequency of
.1% were excluded using PLINK. The putative de novo
CNVs were validated with the median z-score outlier method
(24), software freely available at http://x004.psycm.uwcm.ac.
uk/~dobril/z_scores_cnvs. The z-score histograms of CNVs
withmarginal z-scoresweremanually inspected. For all putative
de novoCNVs, the LRRandB-allele frequencieswere also visu-
ally inspected using Illumina Genome Studiov2011.1 software.
Validation of all remaining putative de novo CNVs was per-
formed using real-time PCR based on SYBR-Green I fluores-
cence with at least three primer sets per CNV. All samples
were amplified using Sensimix kit (Bioline, UK), and data
were analysed using Rotor-Gene Q series software. Each
primer set was compared with a primer set outside the CNV
which served as ‘control’ and data were normalized using
delta Ct (cycle threshold) values.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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